Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) is a clinical-stage biopharmaceutical company that is developing tailored treatments for patients suffering from mental health conditions and neurological disorders by leveraging its Precision Psychiatry Platform, which applies data science and analytics to data gathered by neurocognitive assessments, electroencephalography and wearable devices. The Company’s approach is designed to increase the likelihood of clinical success and commercial impact of its product candidates by using individual patients’ neurobiological profiles to identify more homogeneous patient groups. Alto’s current pipeline consists of five clinical-stage assets initially targeting major depressive disorder (MDD) and schizophrenia populations identified by independent brain-based biomarkers.